Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
March 19 2024 - 8:30AM
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical
company focused on the development and commercialization of
therapeutics for central nervous system (CNS) disorders, today
announced the promotion of Michael Halstead, J.D. to the position
of President. Mr. Halstead is currently serving as Executive Vice
President and General Counsel. In this newly created leadership
role, Mr. Halstead will oversee several functions within the
Company including legal, human resources, manufacturing &
supply chain, quality, compliance, information technology, and
external innovation. He will continue to report to Dr. Sharon
Mates, Chairman and Chief Executive Officer.
“Michael is an exceptional leader who has been instrumental in
Intra-Cellular Therapies’ strong growth over the last decade,” said
Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.
“His knowledge of the Company and broad industry experience has
contributed to our success and helped to establish our strong
foundation for future growth. I look forward to continuing to work
with him in his new role as we further build on our commercial
success and advance our broad pipeline.”
Mr. Halstead is a seasoned healthcare executive, with deep
experience in various aspects of the biopharmaceutical industry. He
joined Intra-Cellular Therapies in 2014 as Senior Vice President
and General Counsel and was promoted to Executive Vice President
and General Counsel in 2019. During his tenure, he has assumed
increasing oversight responsibilities for many company functions.
Prior to joining Intra-Cellular Therapies, Mr. Halstead served in
leadership roles at Warner Chilcott plc, including Senior Vice
President, Corporate Development, where he directed the company’s
corporate development, legal and human resources functions. Prior
to that, Mr. Halstead was an attorney with Davis Polk &
Wardwell.
Intra-Cellular Therapies also announced that Senior Vice
President and Chief Financial Officer, Larry Hineline, will be
retiring after more than 20 years of service. Mr. Hineline has
served as Chief Financial Officer since June 2002. The Company has
initiated an external search for a new Chief Financial Officer and
Mr. Hineline has agreed to remain with the Company through the
process to ensure a smooth transition.
“I am grateful for Larry’s significant contributions over the
years as ITCI evolved from a private company to the fully
integrated public biopharmaceutical company it is today,” said Dr.
Mates. “On behalf of the Board and the entire company we thank him
for his dedication and wish him all the best in his well-deserved
retirement.”
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company
founded on Nobel prize-winning research that allows us to
understand how therapies affect the inner-workings of cells in the
body. The company leverages this intracellular approach to develop
innovative treatments for people living with complex psychiatric
and neurologic diseases. For more information, please
visit www.intracellulartherapies.com.
Contact:
Intra-Cellular Therapies, Inc.Juan Sanchez, M.D. Vice President,
Corporate Communications and Investor Relations646-440-9333
Burns McClellan, Inc.Cameron
Radinoviccradinovic@burnsmc.com646-930-4406
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2023 to Apr 2024